Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for spinal pain in axial spondyloarthritis
NCT03136861Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Secukinumab 150 mg with Placebo (2 arms). Primary endpoint: Spinal Pain Numerical Rating Scale Score at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03136861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136861.